Q-omics provides the consensus-scored PPIAL4G profile across patient tissues and cancer cell-line models. PPIAL4G expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PPIAL4G is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, PPIAL4G RNA expression shows 6,244 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, KIRC, and STAD as cancer lineages where PPIAL4G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAL4G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAL4G survival associations across molecular data types. PPIAL4G RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAL4G RNA expression–survival associations across cancer types. High PPIAL4G expression shows unfavorable associations in MESO, BLCA, LIHC, ACC and KIRC, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for PPIAL4G RNA expression.
This table summarizes PPIAL4G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAL4G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAL4G shows lower tumor expression in PAAD and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher PPIAL4G RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p < 0.001).
This table shows molecular features associated with PPIAL4G in patient tissues and cancer cell lines. In patient samples, PPIAL4G shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PPIAL4G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
